Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based compensation (Tables)

Stock-based compensation (Tables)

6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Total Stock-Based Compensation Expense Related to Share-Based Awards under the Pieris Plan

Total stock-based compensation expense, related to all share-based awards under the Pieris Plan to executive officers, directors, employees and consultants recognized for the three and six months ended June 30, 2015, was comprised of the following:


	Three months ended		Six months ended
	June 30, 2015		June 30, 2015
Research and Development	$	78,551	$	129,590
General and administrative		189,488		355,785

Total stock-option expense	$	268,039	$	485,375

Schedule of Weighted-Average Assumptions Used for Calculating Value of Options Granted

The fair value of option grants was estimated using the Black-Scholes model. The following table describes the weighted-average assumptions used for calculating the value of options granted for the three and six months ended June 30, 2015:


	Three months ended			Six months ended
	June 30, 2015			June 30, 2015
Forfeiture rate		6.0	%		6.0	%
Dividend yield		0.0	%		0.0	%
Expected volatility		73.7	%		74.1	%
Weighted average risk-free interest rate		1.73	%		1.71	%
Expected term		5.3 - 5.8 years			5.3 - 5.8 years

Schedule of Information Regarding Stock Option Activity

A summary of the Company’s stock option activity and related information is as follows:


	Number of shares		Weighted- Average Exercise Price		Weighted- Average Contractual Life
Outstanding at December 31, 2014		2,519,500	$	2.00		5.6 - 5.8 years
Options granted		25,000	$	2.85		5.8 years
Options exercised		—		—		—
Options cancelled or expired		—		—		—
Outstanding at March 31, 2015		2,544,500	$	2.01		5.6 - 5.8 years
Options granted		72,235	$	2.89		5.3 - 5.8 years
Options exercised		—	$	—		—
Options cancelled or expired		—	$	—		—
Outstanding at June 30, 2015		2,616,735	$	2.03		5.3 - 5.8 years
Vested at June 30, 2015		799,068	$	2.03		—
Expected to vest after June 30,2015		1,708,607	$	2.03		—
Exercisable at June 30, 2015		799,068	$	2.03		—